Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin added to intravenous furosemide for acute heart failure congestion
ISRCTN17064177Phase 3Completed
- Sponsor
- Vasile Goldis Western University of Arad
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dapagliflozin in Acute Heart Failure (AHF), sponsored by Vasile Goldis Western University of Arad. Primary endpoints: Congestion relief from baseline to discharge, In-hospital safety and 2 more. Started Oct 2021; status: completed.
02
Drugs
dapagliflozin
03
Conditions
Acute Heart Failure (AHF)
Beyond the preview
Go deeper on ISRCTN17064177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN17064177.